Advertisement

Topics

Jubilant Biosys Becomes the First Company in India to Install Agilent's RapidFire/MS Screening Platform

06:12 EDT 19 Oct 2016 | PR Newswire

BENGALURU, October 19, 2016 /PRNewswire/ --

Jubilant Biosys is proud to announce the addition of Agilent Technologies' RapidFire/MS screening technology to its Integrated Drug Discovery Platform.

     (Logo: http://photos.prnewswire.com/prnh/20160107/783587 )
     (Logo: http://photos.prnewswire.com/prnh/20161019/430304LOGO )

RapidFire is a robust solid phase extraction technology that enables fast label-free detection of native compounds by mass spectrometry in a wide range of in vitro assays, DMPK/ADME studies, hit/lead applications for drug discovery across a broad spectrum of therapeutic areas and also for screening difficult targets that are not amenable to labeled assays. Jubilant Biosys's Bengaluru facility will be the first in India to be equipped with Agilent's state-of-the-art RapidFire High-Throughput Mass Spectrometry system technology.

"The installation of the Agilent RapidFire platform shows Jubilant's continued commitment to make the necessary investments with an objective to remain on the cutting edge of drug discovery. This platform will enable us to increase our productivity and to enhance our capabilities to successfully meet the needs of our clients," said Steven Hutchins, President, Jubilant Biosys (Drug Discovery Solutions).

"Agilent RapidFire solution enables our clients with increased accuracy, provides faster results, better economic value, enhanced analysis capabilities, improved efficiency while maintaining robustness and we are pleased to see Jubilant Biosys being the first organization in India to take advantage of this cutting-edge technology," said Bharat Bhardwaj, Country Manager, Agilent Technologies.

About Jubilant Drug Discovery Solutions (JDDS) 

JDDS comprises of Jubilant Biosys, Jubilant Chemsys and Jubilant Discovery Services and has presence in India in Bangalore, Noida and in Malvern (USA). These subsidiaries of Jubilant Life Sciences Ltd employ over 625 employees and have demonstrated expertise in multiple therapeutic areas of Oncology, Metabolic Disorders, Pain & Inflammation, CNS & others. The business model includes proprietary in-house innovation, strategic investments as well as drug discovery services as the core components which are available for collaborative research, partnership and out-licensing. http://www.jubilantbiosys.com; http://www.jchemsys.com; http://www.jubl.com

About Agilent Technologies 

Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent's expertise and trusted collaboration give them the highest confidence in our solutions.

Agilent focuses its expertise on six key markets, where we help our customers achieve their goals: Food, Environmental and Forensics, Pharmaceutical, Diagnostics, Chemical and Energy, Research. Visit http://www.agilent.com.

For business enquiries: bd@jubilantbiosy.com

SOURCE Jubilant Biosys

NEXT ARTICLE

More From BioPortfolio on "Jubilant Biosys Becomes the First Company in India to Install Agilent's RapidFire/MS Screening Platform"

Quick Search
Advertisement
 

Relevant Topics

Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antiretroviral therapy
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...